These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 14615102

  • 1. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Metz L, Page S.
    Lancet; 2003 Nov 08; 362(9395):1513. PubMed ID: 14615102
    [No Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB.
    Neurology; 2003 Feb 25; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract] [Full Text] [Related]

  • 3. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar 25; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 4. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H, Jensen HB, Stenager E.
    Ugeskr Laeger; 2015 May 11; 177(20):956-60. PubMed ID: 26535431
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sativex for the management of multiple sclerosis symptoms.
    Perras C.
    Issues Emerg Health Technol; 2005 Sep 11; (72):1-4. PubMed ID: 16317825
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M.
    Mult Scler; 2004 Aug 11; 10(4):417-24. PubMed ID: 15327040
    [Abstract] [Full Text] [Related]

  • 11. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T.
    Neurodegener Dis Manag; 2019 Apr 11; 9(2s):1-2. PubMed ID: 30657019
    [Abstract] [Full Text] [Related]

  • 12. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B.
    Neurologia; 2014 Jun 11; 29(5):257-60. PubMed ID: 24035293
    [Abstract] [Full Text] [Related]

  • 13. Cannabis and cannabinoids.
    Med Lett Drugs Ther; 2016 Aug 01; 58(1500):97-8. PubMed ID: 27466748
    [No Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH.
    Neurology; 2002 May 14; 58(9):1404-7. PubMed ID: 12011290
    [Abstract] [Full Text] [Related]

  • 15. The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Saccà F, Pane C, Carotenuto A, Massarelli M, Lanzillo R, Florio EB, Brescia Morra V.
    J Neurol Sci; 2016 Sep 15; 368():349-51. PubMed ID: 27538663
    [No Abstract] [Full Text] [Related]

  • 16. Are cannabinoids effective in multiple sclerosis?
    Meza R, Peña J, García K, Corsi O, Rada G.
    Medwave; 2017 Mar 10; 17(Suppl1):e6865. PubMed ID: 28306712
    [Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A, Broughton J.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec 10; 16(6):771-779. PubMed ID: 26750641
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP.
    Expert Opin Pharmacother; 2006 Apr 10; 7(5):607-15. PubMed ID: 16553576
    [Abstract] [Full Text] [Related]

  • 20. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G, Constantinescu CS.
    Expert Opin Biol Ther; 2012 Nov 10; 12(11):1517-31. PubMed ID: 22954177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.